CK1α, CDK7, CDK9

Class

Small molecule multi-kinase inhibitor

Pathway

RNA Pol II transcriptional regulation / MDM2 expression

This mechanism describes a small-molecule inhibitor that simultaneously blocks three kinases—casein kinase 1 alpha (CK1α), and the transcriptional cyclin-dependent kinases CDK7 and CDK9. CDK7 and CDK9 regulate RNA polymerase II (RNA Pol II), the enzyme that transcribes protein-coding genes into messenger RNA. They do so by phosphorylating the polymerase's carboxy-terminal domain at different stages of the transcription cycle, allowing it to initiate and then elongate along DNA efficiently. Genes encoding short-lived regulatory proteins, including some oncogenic drivers and MDM2 (a protein that promotes degradation of the tumor-suppressor p53), depend heavily on continuous, efficient transcription to maintain their levels. Blocking CDK7/CDK9 preferentially lowers output from these genes. CK1α contributes an additional layer, influencing p53 stability and turnover through separate signaling inputs. Combining inhibition of these three kinases is intended to suppress oncogenic transcriptional programs while reactivating p53-dependent tumor suppression by reducing MDM2. This approach is relevant to cancers, particularly hematologic malignancies, where tumor cells remain dependent on high transcriptional output and where p53 function is intact but suppressed rather than mutated. Because CDK7 and CDK9 are broadly required for transcription in most dividing cells, this class of mechanism carries an inherent trade-off between anti-tumor activity and effects on normal proliferating tissue.